People · Operator
Named in public records as an officer, director or promoter · active 2018–2022 · Biotechnology, Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| RYNE Biotechnology Inc. | — | Biotechnology | Series B | $33.0M | $247.9M | 2022 |
| Vascugen, Inc. | — | Biotechnology | Series A | $10.0M | $361.5M | 2019 |
| Tacitus Therapeutics Inc. | — | Pharmaceuticals | Series A | $5.0M | $154.9M | 2019 |
| Dianomi Therapeutics, Inc. | — | Biotechnology | Pre-Seed | $185K | $10.2M | 2018 |
Carter Cliff at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Carter Cliff on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Jeffrey Kennedy | 2 | 3 |
| Jeff Jonas | 1 | 5 |
| Jeff Goater | 1 | 4 |
| Erik Lium | 1 | 3 |
| William Murphy | 1 | 2 |
| David Fallace | 1 | 2 |
| Marvin Yoder | 1 | 1 |
| Tom Novak | 1 | 1 |
| Thomas Novak | 1 | 1 |
| Kurtis Knapp | 1 | 1 |
| Barry Kurokawa | 1 | 1 |
| Peter Fuhrken | 1 | 1 |
| Howard Federoff | 1 | 1 |
| Nick Manusos | 1 | 1 |
| Martin Ostrowski | 1 | 1 |
| Jonathan Yeh | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.